The higher the ITGB2 expression, the greater the feasibility of targeting macrophages; additionally, we found that assessing ESCC patients' immune responses to therapy via ITGB2 expression is viable. The gene discussed is ITGB2; the disease is esophageal squamous cell carcinoma.